Horizon Pharma PLC (HZNP) Rating Increased to Buy at ValuEngine
Horizon Pharma PLC (NASDAQ:HZNP) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.
A number of other analysts have also weighed in on the stock. Piper Jaffray Companies set a $18.00 target price on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Sunday. Zacks Investment Research lowered shares of Horizon Pharma PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Jefferies Group LLC restated a “buy” rating and set a $16.00 target price on shares of Horizon Pharma PLC in a research note on Thursday, October 5th. Cowen and Company reaffirmed a “buy” rating on shares of Horizon Pharma PLC in a report on Thursday, September 28th. Finally, Goldman Sachs Group, Inc. (The) initiated coverage on Horizon Pharma PLC in a report on Thursday, September 28th. They issued a “buy” rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the company. Horizon Pharma PLC presently has a consensus rating of “Buy” and an average target price of $18.00.
Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at 13.78 on Monday. The stock has a 50 day moving average of $13.09 and a 200-day moving average of $12.69. The company’s market capitalization is $2.25 billion. Horizon Pharma PLC has a 12-month low of $9.45 and a 12-month high of $21.98.
Horizon Pharma PLC (NASDAQ:HZNP) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The firm had revenue of $289.51 million for the quarter, compared to analyst estimates of $237.01 million. During the same period in the prior year, the firm earned $0.56 earnings per share. The business’s quarterly revenue was up 12.5% compared to the same quarter last year. Analysts predict that Horizon Pharma PLC will post $1.07 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Horizon Pharma PLC (HZNP) Rating Increased to Buy at ValuEngine” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/18/horizon-pharma-plc-hznp-rating-increased-to-buy-at-valuengine.html.
Several hedge funds have recently bought and sold shares of HZNP. Bank of Montreal Can boosted its holdings in shares of Horizon Pharma PLC by 16.3% in the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 1,378 shares during the period. Sheaff Brock Investment Advisors LLC boosted its holdings in shares of Horizon Pharma PLC by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 500 shares during the period. Family Management Corp acquired a new stake in shares of Horizon Pharma PLC in the second quarter valued at approximately $131,000. Ballentine Partners LLC acquired a new stake in shares of Horizon Pharma PLC in the second quarter valued at approximately $139,000. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of Horizon Pharma PLC in the first quarter valued at approximately $151,000. 82.32% of the stock is owned by institutional investors and hedge funds.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Stock Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related stocks with our FREE daily email newsletter.